摘要
糖尿病患病率逐年呈增长趋势。据统计,目前我国糖尿病人群接近4000万,患病率上升至3.5%,较20年前增加5倍。预计到2025年我国将成为仅次于印度的第二大糖尿病患者国家。糖尿病前期包括空腹血糖调节受损和糖耐量异常,每年有7.0%~11.0%的糖尿病前期患者发展为糖尿病,其糖尿病年发病率约为正常人群的6倍。
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2010年第8期754-755,共2页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
参考文献16
-
1Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, lore-diabetes,and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology(ESC) and of the European Association for the Study of Diabetes(EASD). Eur Heart J,2007,28:88-136.
-
2Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drugeluting stents. Lancet, 2004,364 : 583-591.
-
3Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis:results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol, 2005,45 : 954-959.
-
4Jimenez-Quevedo P, Sabate M, Angiolillo DJ, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J, 2007,28 : 1946- 1952.
-
5Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation, 2008,118: 2277-2285.
-
6Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent :a TAXUS Ⅱ, Ⅳ,Ⅴ and Ⅵ meta-analysis of 3,445 patients followed for up to 3 years. J Am Coil Cardiol, 2007,49 : 1043-1051.
-
7Ong AT, Aoki J, van Mieghem CA, et al. Comparison of short-(one month) and long-(twelve months) term outcomes of sirolimus versus paelitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol, 2005,96: 358-362.
-
8King SB 3rd,Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol, 2008,51 : 172- 209.
-
9Daeraen J, Kuck KH, Macaya C, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus:3-year follow-up of the ARTS-Ⅱ (Arterial Revascularization Therapies Study-Part Ⅱ ) trial. J Am Coll Cardiol, 2008, 52:1957-1967.
-
10Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360 : 961-972.
二级参考文献8
-
1Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation, 1979,59:8 -13.
-
2Lowe LP, Liu K, Greenland O, et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. Diabetes Care, 1997,20 : 163-169.
-
3Lauruschkat AH, Arnrich B, Albert AA, et al. Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. Circulation, 2005, 112: 2397- 2402.
-
4Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care, 1993,16:642- 652.
-
5Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in southern Germany: target populations for efficient screening: the KORA survey 2000. Diabetologia, 2003,46: 182-189.
-
6American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care,2004,27( Suppl 1 ) :S11-S14.
-
7Abramov D, Tamariz MG, Fremes SE, et al. Trends in coronary artery bypass surgery results: a recent 9-year study. Ann Thorac Surg, 2000,70: 84-90.
-
8Taubert G, Winkelmann BR, Schleiffer T, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J, 2003,145 : 285 -291.
共引文献5
-
1曾姣娥,杨泉.冠心病患者糖代谢异常调查分析[J].临床内科杂志,2010,27(8):569-569. 被引量:1
-
2罗瑞萍,蒋利,徐颖杰,岳静雯,沈泽宁.糖代谢正常冠状动脉性心脏病患者随访3年内的糖代谢变化对预后的影响[J].上海医学,2014,37(1):50-53.
-
3侯卫涛,彭跃华,周俐,孙红蕾,毕美娟.糖耐量减低对急性冠脉综合征介入术后患者预后的影响[J].山西医科大学学报,2015,46(1):41-44. 被引量:2
-
4褚晓波.冠心病合并糖耐量异常患者冠状动脉病变的特点分析[J].中华危重病急救医学,2015,27(12):1013-1014. 被引量:10
-
5杨群娣,阮晔,刘丹妮,刘晓侠,郑杨,施燕.上海市35岁及以上未诊断糖尿病人群的血糖特征及预后危险因素现状[J].中国慢性病预防与控制,2019,27(8):589-592. 被引量:3
同被引文献26
-
1李明霞,朱丽,任涛.二甲双胍与胰岛素联合治疗肥胖2型糖尿病的临床观察[J].华西医学,2007,22(4):797-798. 被引量:2
-
2刘丹,傅祖植.二甲双胍临床应用中的几个问题[J].中华糖尿病杂志(1006-6187),2005,13(2):149-150. 被引量:38
-
3颜学洁,温宁绥.吡格列酮治疗2型糖尿病52例临床观察[J].实用中西医结合临床,2006,6(2):21-21. 被引量:2
-
4王露,宁洁.二甲双胍对肥胖2型糖尿病患者血清C反应蛋白补体C3的影响[J].山西医药杂志,2006,35(10):888-889. 被引量:2
-
5Yang W,Lu J,Weng J,et al.Prevalence pf diabetes amang men and women in China[J].N Engl J Med,2010;362(12):1090-1101.
-
6I-Iotamisligil G. Inflammation and metabolic disorders. Nature,2006,444(7121):860-867.
-
7Jeon YK,Kim MR,Huh JE,et al. Cystatin C as an early biomark- er of nephropathy in patients with type 2 diabetes[J]. J Korean Med Sci,2011,26(2) :258-263.
-
8Poege U,Stoschus B ,Stoffel wagner B ,et al. Cystatin C as an endogenous marker of glomerular fihration rate in renal transplant patients [J]. Kidney Blood Pressure Res ,2008,26( 1 ) : 55-60.
-
9I-Iotamisligil G. Inflammation and metabolic disorders. Nature,2006,444(7121):860-867.
-
10Jeon YK,Kim MR,Huh JE,et al. Cystatin C as an early biomark- er of nephropathy in patients with type 2 diabetes[J]. J Korean Med Sci,2011,26(2) :258-263.
引证文献4
-
1陈清顺,刘文坚,方淑华.吡格列酮治疗2型糖尿病的疗效及其对胰岛素敏感性的影响[J].现代诊断与治疗,2011,22(6):339-340. 被引量:1
-
2袁妙兰.二甲双胍联合比格列酮治疗肥胖新诊断2型糖尿病患者的疗效观察[J].中国医药导刊,2012,14(3):433-434. 被引量:10
-
3周肖英,韦勇.联合检测血Cys-C和IL-6在糖尿病肾损害中的应用价值[J].中国现代医药杂志,2012,14(7):48-50. 被引量:6
-
4医学论文实用性的判断[J].中国现代医药杂志,2012,14(7):50-50.
二级引证文献17
-
1刘晗,高继东.血清胱抑素、视黄醇结合蛋白和白细胞介素-6联合检测在老年人糖尿病早期肾损害中的应用[J].中国老年学杂志,2014,34(5):1391-1392. 被引量:7
-
2庄惊奇.肥胖、血脂、血糖与2型糖尿病脂肪肝(DFL)的关系[J].中国医药导刊,2013,15(4):590-590. 被引量:4
-
3徐风梅.盐酸吡格列酮对2型糖尿病患者胰岛β细胞功能及血管内皮功能的影响分析[J].中国医药导刊,2013,15(3):471-472. 被引量:4
-
4刘芹,李青,李梦真,史丽雯,张婷婷,邱家学.吡格列酮联合二甲双胍治疗2型糖尿病效果的meta分析[J].上海医药,2014,35(7):29-35. 被引量:9
-
5熊彬,魏任雄,郭维英,廖于峰.2型糖尿病患者白细胞介素-6和可溶性细胞黏附分子-1及血清超敏C-反应蛋白的血清水平分析[J].中国慢性病预防与控制,2014,22(4):408-410. 被引量:8
-
6刘春英,刘彩霞.采用胰岛素泵治疗2型糖尿病的疗效及对患者生活质量的影响[J].中国基层医药,2015,22(3):419-421. 被引量:13
-
7孙文强,厉东亚.固肾平糖方联合西医治疗肥胖2型糖尿病疗效观察[J].现代中西医结合杂志,2015,24(17):1881-1883. 被引量:4
-
8王森.二甲双胍对肥胖2型糖尿病患者抵抗素、胰岛素样生长因子Ⅰ及炎性因子的影响[J].海南医学院学报,2016,22(2):154-156. 被引量:12
-
9应俊,张晓辉,陈江华,陈光明.西格列汀对糖尿病合并肾损伤患者肾功能及γ-谷氨酰转移酶的影响[J].中国新药与临床杂志,2016,35(4):273-276. 被引量:5
-
10罗建平,高丽萍,李博慧,张立梅,魏小慧.吡格列酮合并二甲双胍治疗新诊断的2型糖尿病临床效果分析[J].中国实用医药,2016,11(9):152-153. 被引量:5
-
1雷军荣,何勇,张宝宁,蔺军芳,王晓武,张卫达.冠状动脉旁路移植术97例[J].第四军医大学学报,2005,26(23):2141-2141.
-
2陈成伟.脂肪肝是否要用药治疗[J].江苏卫生保健(今日保健),2008(1):19-19.
-
3骆永娟,关欣,张玉兰.实时三维超声心动图评价冠状动脉旁路移植术前后左心室功能[J].中华老年心脑血管病杂志,2010,12(8):693-694. 被引量:1
-
4吴淼,蒋学俊,文英,任珊,贺轶宇.冠心病患者经皮冠状动脉介入治疗后再次冠状动脉血运重建的影响因素分析[J].武汉大学学报(医学版),2014,35(3):414-417. 被引量:6
-
5杜纪兵,丛洪良,陈树涛.急性心肌梗死直接PCI与其他治疗方法的疗效比较[J].实用心脑肺血管病杂志,2004,12(5):306-308. 被引量:4
-
6张愉.老年糖尿病肾病研究进展[J].中国医药导报,2011,8(32):15-17. 被引量:12
-
7邵春海,刘景芳,苏健光,张家瑛.高尿酸血症与代谢综合征各组分间的关系及营养治疗[J].上海医药,2013,34(5):11-13. 被引量:10
-
8张萍.评论:创造条件用好β受体阻滞剂[J].中华心脏与心律电子杂志,2014,2(1):59-59.
-
9张隽义.整合调节血糖,阻断心血管事件链发展[J].中华养生保健,2017,0(2):10-11.
-
10董莉.踝臂指数对非ST段抬高急性冠脉综合征患者预后判断的价值[J].中国现代药物应用,2010,4(14):95-96.